Zobrazit více v PubMed
Aboulaila M., Nakamura K., Govind Y., Yokoyama N., Igarashi I. Evaluation of the in vitro growth-inhibitory effect of epoxomicin on Babesia parasites. Vet. Parasitol. 2010;167:19–27.
PubMed
Adams J. The proteasome: a suitable antineoplastic target. Nat. Rev. Canc. 2004;4:349–360.
PubMed
Arastu-Kapur S., Anderl J.L., Kraus M., Parlati F., Shenk K.D., Lee S.J., Muchamuel T., Bennett M.K., Driessen C., Ball A.J., Kirk C.J. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin. Canc. Res. 2011;17:2734–2743.
PubMed
Arisue N., Hashimoto T. Phylogeny and evolution of apicoplasts and apicomplexan parasites. Parasitol. Int. 2015;64:254–259.
PubMed
Bedford L., Paine S., Sheppard P.W., Mayer R.J., Roelofs J. Assembly, structure, and function of the 26S proteasome. Trends Cell Biol. 2010;20:391–401.
PubMed
PMC
Benezra D., Brown A.E., Polsky B., Gold J.W., Armstrong D. Babesiosis and infection with human immunodeficiency virus (HIV) Ann. Intern. Med. 1987;107:944.
PubMed
Bibo-Verdugo B., Jiang Z., Caffrey C.R., O'Donoghue A.J. Targeting proteasomes in infectious organisms to combat disease. FEBS J. 2017;284:1503–1517.
PubMed
Bock R., Jackson L., de Vos A., Jorgensen W. Babesiosis of cattle. Parasitology. 2004;129(Suppl. l):S247–S269.
PubMed
Burki F., Inagaki Y., Bråte J., Archibald J.M., Keeling P.J., Cavalier-Smith T., Sakaguchi M., Hashimoto T., Horak A., Kumar S., Klaveness D., Jakobsen K.S., Pawlowski J., Shalchian-Tabrizi K. Large-scale phylogenomic analyses reveal that two enigmatic protist lineages, telonemia and centroheliozoa, are related to photosynthetic chromalveolates. Genome Biol Evol. 2009;1:231–238.
PubMed
PMC
de Vries E., Corton C., Harris B., Cornelissen A.W., Berriman M. Expressed sequence tag (EST) analysis of the erythrocytic stages of Babesia bovis. Vet. Parasitol. 2006;138:61–74.
PubMed
Demo S.D., Kirk C.J., Aujay M.A., Buchholz T.J., Dajee M., Ho M.N., Jiang J., Laidig G.J., Lewis E.R., Parlati F., Shenk K.D., Smyth M.S., Sun C.M., Vallone M.K., Woo T.M., Molineaux C.J., Bennett M.K. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Canc. Res. 2007;67:6383–6391.
PubMed
Dogovski C., Xie S.C., Burgio G., Bridgford J., Mok S., McCaw J.M., Chotivanich K., Kenny S., Gnädig N., Straimer J., Bozdech Z., Fidock D.A., Simpson J.A., Dondorp A.M., Foote S., Klonis N., Tilley L. Targeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistance. PLoS Biol. 2015;13
PubMed
PMC
Falagas M.E., Klempner M.S. Babesiosis in patients with AIDS: a chronic infection presenting as fever of unknown origin. Clin. Infect. Dis. 1996;22:809–812.
PubMed
Ferrington D.A., Gregerson D.S. Immunoproteasomes: structure, function, and antigen presentation. Prog Mol Biol Transl Sci. 2012;109:75–112.
PubMed
PMC
Froberg M.K., Dannen D., Bakken J.S. Babesiosis and HIV. Lancet. 2004;363:704.
PubMed
Giguere C.J., Schnellmann R.G. Limitations of SLLVY-AMC in calpain and proteasome measurements. Biochem. Biophys. Res. Commun. 2008;371:578–581.
PubMed
PMC
Gohil S., Herrmann S., Günther S., Cooke B.M. Bovine babesiosis in the 21st century: advances in biology and functional genomics. Int. J. Parasitol. 2013;43:125–132.
PubMed
Groll M., Berkers C.R., Ploegh H.L., Ovaa H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure. 2006;14:451–456.
PubMed
Gu Y., Bouwman P., Greco D., Saarela J., Yadav B., Jonkers J., Kuznetsov S.G. Suppression of BRCA1 sensitizes cells to proteasome inhibitors. Cell Death Dis. 2014;5
PubMed
PMC
Haapasalo K., Suomalainen P., Sukura A., Siikamaki H., Jokiranta T.S. Fatal babesiosis in man, Finland, 2004. Emerg. Infect. Dis. 2010;16:1116–1118.
PubMed
PMC
Hildebrandt A., Gray J.S., Hunfeld K.P. Human babesiosis in Europe: what clinicians need to know. Infection. 2013;41:1057–1072.
PubMed
Häselbarth K., Tenter A.M., Brade V., Krieger G., Hunfeld K.P. First case of human babesiosis in Germany - clinical presentation and molecular characterisation of the pathogen. Int J Med Microbiol. 2007;297:197–204.
PubMed
Janouskovec J., Horák A., Oborník M., Lukes J., Keeling P.J. A common red algal origin of the apicomplexan, dinoflagellate, and heterokont plastids. Proc. Natl. Acad. Sci. U. S. A. 2010;107:10949–10954.
PubMed
PMC
Kane R.C., Bross P.F., Farrell A.T., Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncology. 2003;8:508–513.
PubMed
Kane R.C., Farrell A.T., Sridhara R., Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin. Canc. Res. 2006;12:2955–2960.
PubMed
Khare S., Nagle A.S., Biggart A., Lai Y.H., Liang F., Davis L.C., Barnes S.W., Mathison C.J., Myburgh E., Gao M.Y., Gillespie J.R., Liu X., Tan J.L., Stinson M., Rivera I.C., Ballard J., Yeh V., Groessl T., Federe G., Koh H.X., Venable J.D., Bursulaya B., Shapiro M., Mishra P.K., Spraggon G., Brock A., Mottram J.C., Buckner F.S., Rao S.P., Wen B.G., Walker J.R., Tuntland T., Molteni V., Glynne R.J., Supek F. Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. Nature. 2016;537:229–233.
PubMed
PMC
Kim K.B., Crews C.M. From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes. Nat. Prod. Rep. 2013;30:600–604.
PubMed
PMC
Kish-Trier E., Hill C.P. Structural biology of the proteasome. Annu. Rev. Biophys. 2013;42:29–49.
PubMed
PMC
Kisselev A.F., van der Linden W.A., Overkleeft H.S. Proteasome inhibitors: an expanding army attacking a unique target. Chem. Biol. 2012;19:99–115.
PubMed
PMC
Krause P.J., Gewurz B.E., Hill D., Marty F.M., Vannier E., Foppa I.M., Furman R.R., Neuhaus E., Skowron G., Gupta S., McCalla C., Pesanti E.L., Young M., Heiman D., Hsue G., Gelfand J.A., Wormser G.P., Dickason J., Bia F.J., Hartman B., Telford S.R., Christianson D., Dardick K., Coleman M., Girotto J.E., Spielman A. Persistent and relapsing babesiosis in immunocompromised patients. Clin. Infect. Dis. 2008;46:370–376.
PubMed
Kuhn D.J., Chen Q., Voorhees P.M., Strader J.S., Shenk K.D., Sun C.M., Demo S.D., Bennett M.K., van Leeuwen F.W., Chanan-Khan A.A., Orlowski R.Z. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110:3281–3290.
PubMed
PMC
Kupperman E., Lee E.C., Cao Y., Bannerman B., Fitzgerald M., Berger A., Yu J., Yang Y., Hales P., Bruzzese F., Liu J., Blank J., Garcia K., Tsu C., Dick L., Fleming P., Yu L., Manfredi M., Rolfe M., Bolen J. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Canc. Res. 2010;70:1970–1980.
PubMed
LaMonte G.M., Almaliti J., Bibo-Verdugo B., Keller L., Zou B.Y., Yang J., Antonova-Koch Y., Orjuela-Sanchez P., Boyle C.A., Vigil E., Wang L., Goldgof G.M., Gerwick L., O'Donoghue A.J., Winzeler E.A., Gerwick W.H., Ottilie S. Development of a potent inhibitor of the Plasmodium proteasome with reduced mammalian toxicity. J. Med. Chem. 2017;60:6721–6732.
PubMed
PMC
Lantos P.M., Krause P.J. Babesiosis: similar to malaria but different. Pediatr. Ann. 2002;31:192–197.
PubMed
Leiby D.A. Transfusion-transmitted Babesia spp.: bull's-eye on Babesia microti. Clin. Microbiol. Rev. 2011;24:14–28.
PubMed
PMC
Lemieux J.E., Tran A.D., Freimark L., Schaffner S.F., Goethert H., Andersen K.G., Bazner S., Li A., McGrath G., Sloan L., Vannier E., Milner D., Pritt B., Rosenberg E., Telford S., Bailey J.A., Sabeti P.C. A global map of genetic diversity in Babesia microti reveals strong population structure and identifies variants associated with clinical relapse. Nat Microbiol. 2016;1:16079.
PubMed
PMC
Li H., Bogyo M., da Fonseca P.C. The cryo-EM structure of the Plasmodium falciparum 20S proteasome and its use in the fight against malaria. FEBS J. 2016;283:4238–4243.
PubMed
PMC
Li H., O'Donoghue A.J., van der Linden W.A., Xie S.C., Yoo E., Foe I.T., Tilley L., Craik C.S., da Fonseca P.C., Bogyo M. Structure- and function-based design of Plasmodium-selective proteasome inhibitors. Nature. 2016;530:233–236.
PubMed
PMC
Li H., Ponder E.L., Verdoes M., Asbjornsdottir K.H., Deu E., Edgington L.E., Lee J.T., Kirk C.J., Demo S.D., Williamson K.C., Bogyo M. Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity. Chem. Biol. 2012;19:1535–1545.
PubMed
PMC
Lobo C.A., Cursino-Santos J.R., Alhassan A., Rodrigues M. Babesia: an emerging infectious threat in transfusion medicine. PLoS Pathog. 2013;9
PubMed
PMC
Malandrin L., L'Hostis M., Chauvin A. Isolation of Babesia divergens from Carrier cattle blood using in vitro culture. Vet. Res. 2004;35:131–139.
PubMed
Muchamuel T., Basler M., Aujay M.A., Suzuki E., Kalim K.W., Lauer C., Sylvain C., Ring E.R., Shields J., Jiang J., Shwonek P., Parlati F., Demo S.D., Bennett M.K., Kirk C.J., Groettrup M. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat. Med. 2009;15:781–787.
PubMed
Mørch K., Holmaas G., Frolander P.S., Kristoffersen E.K. Severe human Babesia divergens infection in Norway. Int. J. Infect. Dis. 2015;33:37–38.
PubMed
Ord R.L., Lobo C.A. Human babesiosis: pathogens, prevalence, diagnosis and treatment. Curr. Clin. Microbiol. Rep. 2015;2:173–181.
PubMed
PMC
Perner J., Sobotka R., Sima R., Konvickova J., Sojka D., Oliveira P.L., Hajdusek O., Kopacek P. Acquisition of exogenous haem is essential for tick reproduction. Elife. 2016;5
PubMed
PMC
Rosner F., Zarrabi M.H., Benach J.L., Habicht G.S. Babesiosis in splenectomized adults. Review of 22 reported cases. Am. J. Med. 1984;76:696–701.
PubMed
Schnittger L., Rodriguez A.E., Florin-Christensen M., Morrison D.A. Babesia: a world emerging. Infect. Genet. Evol. 2012;12:1788–1809.
PubMed
Schreeg M.E., Marr H.S., Tarigo J.L., Cohn L.A., Bird D.M., Scholl E.H., Levy M.G., Wiegmann B.M., Birkenheuer A.J. Mitochondrial genome sequences and structures aid in the resolution of piroplasmida phylogeny. PLoS One. 2016;11
PubMed
PMC
Simon M.S., Westblade L.F., Dziedziech A., Visone J.E., Furman R.R., Jenkins S.G., Schuetz A.N., Kirkman L.A. Clinical and molecular evidence of atovaquone and azithromycin resistance in relapsed Babesia microti infection associated with rituximab and chronic lymphocytic leukemia. Clin. Infect. Dis. 2017;65:1222–1225.
PubMed
PMC
Stowell C.P., Gelfand J.A., Shepard J.A., Kratz A. Case records of the Massachusetts General Hospital. Case 17-2007. A 25-year-old woman with relapsing fevers and recent onset of dyspnea. N. Engl. J. Med. 2007;356:2313–2319.
PubMed
Tomko R.J., Hochstrasser M. Molecular architecture and assembly of the eukaryotic proteasome. Annu. Rev. Biochem. 2013;82:415–445.
PubMed
PMC
Uhnoo I., Cars O., Christensson D., Nyström-Rosander C. First documented case of human babesiosis in Sweden. Scand. J. Infect. Dis. 1992;24:541–547.
PubMed
Vannier E., Krause P.J. Human babesiosis. N. Engl. J. Med. 2012;366:2397–2407.
PubMed
Vannier E.G., Diuk-Wasser M.A., Ben Mamoun C., Krause P.J. Babesiosis. Infect. Dis. Clin. 2015;29:357–370.
PubMed
PMC
Verdoes M., Florea B.I., Menendez-Benito V., Maynard C.J., Witte M.D., van der Linden W.A., van den Nieuwendijk A.M., Hofmann T., Berkers C.R., van Leeuwen F.W., Groothuis T.A., Leeuwenburgh M.A., Ovaa H., Neefjes J.J., Filippov D.V., van der Marel G.A., Dantuma N.P., Overkleeft H.S. A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. Chem. Biol. 2006;13:1217–1226.
PubMed
Vial H.J., Gorenflot A. Chemotherapy against babesiosis. Vet. Parasitol. 2006;138:147–160.
PubMed
Voges D., Zwickl P., Baumeister W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu. Rev. Biochem. 1999;68:1015–1068.
PubMed
Wormser G.P., Prasad A., Neuhaus E., Joshi S., Nowakowski J., Nelson J., Mittleman A., Aguero-Rosenfeld M., Topal J., Krause P.J. Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection. Clin. Infect. Dis. 2010;50:381–386.
PubMed
Yabsley M.J., Shock B.C. Natural history of zoonotic Babesia: role of wildlife reservoirs. Int J Parasitol Parasites Wildl. 2013;2:18–31.
PubMed
PMC
Yang J., Wang Z., Fang Y., Jiang J., Zhao F., Wong H., Bennett M.K., Molineaux C.J., Kirk C.J. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab. Dispos. 2011;39:1873–1882.
PubMed
Zintl A., Mulcahy G., Skerrett H.E., Taylor S.M., Gray J.S. Babesia divergens, a bovine blood parasite of veterinary and zoonotic importance. Clin. Microbiol. Rev. 2003;16:622–636.
PubMed
PMC